Review
The pharmacologic modulation of 5-fluorouracil with folinic acid, methotrexate, trimetrexate, and n-phosphonacetyl-l-aspartic acid (PALA). Mechanisms of the interactions and clinical data
Affiliations
- PMID: 7727863
Item in Clipboard
Review
The pharmacologic modulation of 5-fluorouracil with folinic acid, methotrexate, trimetrexate, and n-phosphonacetyl-l-aspartic acid (PALA). Mechanisms of the interactions and clinical data
Bull Cancer.
1994 Dec.
No abstract available
Similar articles
-
Biomodulation of Fluorouracil in colorectal cancer.Cancer Invest. 1998;16(4):237-51. doi: 10.3109/07357909809039773. Cancer Invest. 1998. PMID: 9589033 Review.
-
Phase I trial of PALA, methotrexate, fluorouracil, leucovorin, and uridine rescue in patients with advanced cancer. The use of uridine to decrease fluorouracil toxicity.Cancer Invest. 1990;8(2):263-4. doi: 10.3109/07357909009017578. Cancer Invest. 1990. PMID: 2400946 No abstract available.
-
Modulation of 5-fluorouracil with methotrexate and low-dose N-(phosphonacetyl)-L-aspartate (PALA) is inactive in advanced pancreatic carcinoma.Ann Oncol. 1997 Sep;8(9):917-8. doi: 10.1023/a:1008298102758. Ann Oncol. 1997. PMID: 9358946
-
A phase I study of continuous infusion 5-fluorouracil plus calcium leucovorin in combination with N-(phosphonacetyl)-L-aspartate in metastatic gastrointestinal adenocarcinoma.Cancer Res. 1993 Oct 15;53(20):4828-36. Cancer Res. 1993. PMID: 8402669 Clinical Trial.
-
Chemotherapy of advanced cancer of the colon and rectum.Semin Oncol. 1991 Oct;18(5):443-61. Semin Oncol. 1991. PMID: 1925632 Review. No abstract available.